Nemonapride Explained

Nemonapride (エミレース, Emilace (JP)) is an atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in May 1991.[1] Nemonapride acts as a D2 and D3 receptor antagonist, and is also a potent 5-HT1A receptor agonist.[2] It has affinity for sigma receptors.

See also

Notes and References

  1. Web site: Pharmaceuticals and Medical Devices Safety Information No. 265 . Pharmaceuticals and Medical Devices Agency . 26 July 2022 . https://web.archive.org/web/20220726232009/https://www.pmda.go.jp/files/000153478.pdf . 26 July 2022 . January 2010.
  2. Kusumi I, Boku S, Takahashi Y . Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis . Psychiatry and Clinical Neurosciences . 69 . 5 . 243–258 . May 2015 . 25296946 . 10.1111/pcn.12242 . Wiley . 23102204 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Nemonapride".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.